Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Date Issued
2023-08-12
Author(s)
Liu, Geoffrey
Lu, Shun
He, Jianxing
Burotto, Mauricio
Ahn, Myung-Ju
Kim, Dong-Wan
Liu, XiaoQing
Zhao, Yanqiu
Vincent, Sylvie
Yin, Jiani
Ma, Xin
Lin, Huamao M
Popat, Sanjay
Abstract
This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.
Subjects
Alectinib; Anaplastic lymphoma kinase; Brigatinib; Non–small cell lung cancer; Tyrosine kinase inhibitor
Type
journal article